~(131)I-17-丙烯胺基-17-脱甲基格尔德霉素毒副作用的初步观察

目的观察131I-17-丙烯胺基-17-脱甲基格尔德霉素(131I-17-AAG)治疗VX2肝癌移植瘤模型的骨髓及肝脏毒副作用。方法16只新西兰白兔,制成VX2荷肝癌模型后,按完全随机原则分为2组,1组(治疗组)8只,10mCi131I-17-AAG耳缘静脉注射;2组(对照组)8只,为未经治疗的荷瘤兔,1、2组荷瘤兔均分别于第1、2周耳缘静脉采血,进行血常规(白细胞、红细胞、血红蛋白、血小板)及酶学(谷草转氨酶、谷丙转氨酶、碱性磷酸酶、谷氨酰转酞酶)检查。结果2周时白细胞、红细胞和血红蛋白无显著差异(P>0.05),血小板、ALT、AST均有显著差异(P<0.05),碱性磷酸酶、谷氨酰转移酶无显著差异(P>0.05)。结论131I-17-丙烯胺基17脱甲基格尔德霉素(131I-17-AAG)对骨髓造血干细胞及肝功能各项指标有不同程度的影响,且随时间逐步得到恢复。

The Primary Observation of Toxicity and Side-effects of ~(131)I-17-allylamino-17-demethoxygeldanamycin

Objective To investigate the bone marrow side-effect and liver toxicity of the treatment on vx2 transplanted liver cancer model rabbits with 17-allylamino-17-demethoxygel-danamycin. Methods 16 New-Zealand white rabbits were made into VX2 transplanted liver cancer models and devided into two groups randomly. 8 rabbits in the first group (treatment group) were treated with 10 mCi 131I-17-allylamino-17-demethoxygeldanamycin by ear vein injection, and the second group(contrast group) was untreated. 1 week and 2 weeks after injection two groups were examined of white blood cells(WBC), red blood cells(RBC), blood platelet(PLT), hemoglobin (Hb), glutamate-pyruvate transaminase(ALT), glutamic-oxal(o)acetictransaminase (AST) alkaline phosphatase(ALP)γ-glutamyltransferase(GGT). Collected data were analyzed with SPSS14. 0. Results The variance of white blood cells(WBC), red blood cells(RBC), hemoglobin(Hb), alkaline phosphatase (ALP),γ-glutamyltransferase(GGT) were nonsignificant (P > 0.05) in 2 weeks. However, the significance of variance was seen in blood platelet(PLT) , glutamate-pyruvate transaminase(ALT), glutamic-oxal(o)acetic transaminase (AST) at the same time(P<0.05). Conclusion The side-effects of 131I-17-allylamino-17-demethoxygeldanamycin differed in various blood items and improved with time.